Cargando…

Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging

Perfluorocarbon nanoparticles have been reported to deliver oxygen to tumors and reduce hypoxia-induced radioresistance, however few studies have been carried out to study its role in reducing hypoxia-induced chemoresistance. The oxygenation effect also varies dramatically between different perfluor...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Donghui, Beringhs, André O'Reilly, Zhuang, Zhenwu, Joshi, Gaurav, Tran, Thanh Huyen, Claffey, Kevin P., Yuan, Hong, Lu, Xiuling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536783/
https://www.ncbi.nlm.nih.gov/pubmed/31183316
http://dx.doi.org/10.7150/ntno.35935
_version_ 1783421844474298368
author Song, Donghui
Beringhs, André O'Reilly
Zhuang, Zhenwu
Joshi, Gaurav
Tran, Thanh Huyen
Claffey, Kevin P.
Yuan, Hong
Lu, Xiuling
author_facet Song, Donghui
Beringhs, André O'Reilly
Zhuang, Zhenwu
Joshi, Gaurav
Tran, Thanh Huyen
Claffey, Kevin P.
Yuan, Hong
Lu, Xiuling
author_sort Song, Donghui
collection PubMed
description Perfluorocarbon nanoparticles have been reported to deliver oxygen to tumors and reduce hypoxia-induced radioresistance, however few studies have been carried out to study its role in reducing hypoxia-induced chemoresistance. The oxygenation effect also varies dramatically between different perfluorocarbon formulations and protocols, and there have been no efficient tools to monitor dynamic changes of tumor oxygenation non-invasively. Our goal was to promote tumor oxygenation using perfluorooctyl bromide (PFOB) nanoemulsion and to assess its role in sensitizing tumors to cisplatin treatment. A novel optical imaging protocol was also created to monitor the dynamic changes of tumor oxygenation in real-time. Methods: PFOB nanoemulsion with high oxygen-carrying capacity was prepared and administered to tumor-bearing mice intravenously. Tumor oxygenation was monitored using optical imaging with a hypoxia probe injected intratumorally, thus the oxygenation dynamics and best oxygenation protocol were determined. Various treatment groups were studied, and the tumor growth was monitored to evaluate the role of oxygenation in sensitizing tumors to cisplatin treatment. Results: PFOB nanoemulsion with and without pre-oxygenation along with carbogen breathing resulted in much better tumor oxygenation compared to carbogen breathing alone, while PFOB with air breathing did not show significant increase in tumor oxygenation. Pre-oxygenated PFOB with carbogen breathing produced the most effective oxygenation as early as 5 min post administration. In vitro and in vivo data showed preoxygenated PFOB nanoemulsion with carbogen breathing could increase cisplatin-mediated apoptosis of cancer cells and inhibited tumor growth at a low dose of cisplatin (1 mg/kg) treatment. Furthermore, the treatment did not induce nephrotoxicity. Conclusions: Preoxygenated PFOB nanoemulsion with carbogen breathing can effectively increase tumor oxygenation, which has a great potential to prevent/overcome hypoxia-induced chemotherapy resistance. In addition, optical imaging with intratumoral injection of the hypoxia probe was an efficient tool to monitor tumor oxygenation dynamics during PFOB administration, providing better understanding on oxygenation effects under different protocols.
format Online
Article
Text
id pubmed-6536783
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-65367832019-06-10 Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging Song, Donghui Beringhs, André O'Reilly Zhuang, Zhenwu Joshi, Gaurav Tran, Thanh Huyen Claffey, Kevin P. Yuan, Hong Lu, Xiuling Nanotheranostics Research Paper Perfluorocarbon nanoparticles have been reported to deliver oxygen to tumors and reduce hypoxia-induced radioresistance, however few studies have been carried out to study its role in reducing hypoxia-induced chemoresistance. The oxygenation effect also varies dramatically between different perfluorocarbon formulations and protocols, and there have been no efficient tools to monitor dynamic changes of tumor oxygenation non-invasively. Our goal was to promote tumor oxygenation using perfluorooctyl bromide (PFOB) nanoemulsion and to assess its role in sensitizing tumors to cisplatin treatment. A novel optical imaging protocol was also created to monitor the dynamic changes of tumor oxygenation in real-time. Methods: PFOB nanoemulsion with high oxygen-carrying capacity was prepared and administered to tumor-bearing mice intravenously. Tumor oxygenation was monitored using optical imaging with a hypoxia probe injected intratumorally, thus the oxygenation dynamics and best oxygenation protocol were determined. Various treatment groups were studied, and the tumor growth was monitored to evaluate the role of oxygenation in sensitizing tumors to cisplatin treatment. Results: PFOB nanoemulsion with and without pre-oxygenation along with carbogen breathing resulted in much better tumor oxygenation compared to carbogen breathing alone, while PFOB with air breathing did not show significant increase in tumor oxygenation. Pre-oxygenated PFOB with carbogen breathing produced the most effective oxygenation as early as 5 min post administration. In vitro and in vivo data showed preoxygenated PFOB nanoemulsion with carbogen breathing could increase cisplatin-mediated apoptosis of cancer cells and inhibited tumor growth at a low dose of cisplatin (1 mg/kg) treatment. Furthermore, the treatment did not induce nephrotoxicity. Conclusions: Preoxygenated PFOB nanoemulsion with carbogen breathing can effectively increase tumor oxygenation, which has a great potential to prevent/overcome hypoxia-induced chemotherapy resistance. In addition, optical imaging with intratumoral injection of the hypoxia probe was an efficient tool to monitor tumor oxygenation dynamics during PFOB administration, providing better understanding on oxygenation effects under different protocols. Ivyspring International Publisher 2019-05-22 /pmc/articles/PMC6536783/ /pubmed/31183316 http://dx.doi.org/10.7150/ntno.35935 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Song, Donghui
Beringhs, André O'Reilly
Zhuang, Zhenwu
Joshi, Gaurav
Tran, Thanh Huyen
Claffey, Kevin P.
Yuan, Hong
Lu, Xiuling
Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging
title Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging
title_full Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging
title_fullStr Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging
title_full_unstemmed Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging
title_short Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging
title_sort overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536783/
https://www.ncbi.nlm.nih.gov/pubmed/31183316
http://dx.doi.org/10.7150/ntno.35935
work_keys_str_mv AT songdonghui overcominghypoxiainducedchemoresistancetocisplatinthroughtumoroxygenationmonitoredbyopticalimaging
AT beringhsandreoreilly overcominghypoxiainducedchemoresistancetocisplatinthroughtumoroxygenationmonitoredbyopticalimaging
AT zhuangzhenwu overcominghypoxiainducedchemoresistancetocisplatinthroughtumoroxygenationmonitoredbyopticalimaging
AT joshigaurav overcominghypoxiainducedchemoresistancetocisplatinthroughtumoroxygenationmonitoredbyopticalimaging
AT tranthanhhuyen overcominghypoxiainducedchemoresistancetocisplatinthroughtumoroxygenationmonitoredbyopticalimaging
AT claffeykevinp overcominghypoxiainducedchemoresistancetocisplatinthroughtumoroxygenationmonitoredbyopticalimaging
AT yuanhong overcominghypoxiainducedchemoresistancetocisplatinthroughtumoroxygenationmonitoredbyopticalimaging
AT luxiuling overcominghypoxiainducedchemoresistancetocisplatinthroughtumoroxygenationmonitoredbyopticalimaging